Regramostim, GM-CSF

Specification Drug Information Related Products

Cat#:	THP-0186
Product Name:	Regramostim, GM-CSF
Description:	Human GM-CSF (Granulocyte/Monocyte-Colony Stimulating Factor) is a differentially glycosylated factor produced mainly by activated T cells and macrophages. Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too. GM-CSF stimulates proliferation, activation and differentiation of macrophages and granulocytes and their progenitors.
Sequences:	APARSPSPST QPWEHVNAIQ EARRLLNLSR DTAAEMNETV EVISEMFDLQ EPTCLQTRLE LYKQGLRGSL TKLKGPLTMM ASHYKQHCPP TPETSCATQT ITFESFKENL KDFLLVIPFD CWEPVQE
Species:	Human
Molecular Weight:	14305.3332
Source:	CHO Cells
Purity:	>99% by SDS-Page and HPLC analysis
Cas No:	127757-91-9
Formula:	C637H1003N171O187S8
Endotoxin Level:	<0.001 EU per 1 μg of the peptide by the LAL method

Drug Name:	Regramostim
Applications:	Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.
Examples of Clinical Use:	Adverse effects (chemotherapy) and bone marrow transplant
Pharmacodynamics:	Not Available
Mechanism of action:	This drug activates mononuclear phagocytes, promotes migration of epithelial cells, and further regulates cytokine production. In 2 recent placebo-controlled studies involving venous leg ulceration, subcutaneous perilesional injections of recombinant human granulocyte-macrophage colony-stimulating factor were found to be significantly better than placebo in the time to complete wound healing. In other studies, recombinant human granulocyte-macrophage colony-stimulating factor was administered topically to wounds. Several case reports have also demonstrated the use of recombinant human granulocyte-macrophage colony-stimulating factor for postsurgical wounds, chronic leg ulcers of sickle cell anemia patients, and refract and refractory pyoderma gangrenosum.
Affected organisms:	Not Available
Targets:	Target 1. Granulocyte-macrophage colony-stimulating factor receptor subunit alpha; Target 2. GM-CSF receptor alpha subunit